Stay updated on BI 655130 Dosing in Palmoplantar Pustulosis Clinical Trial
Sign up to get notified when there's something new on the BI 655130 Dosing in Palmoplantar Pustulosis Clinical Trial page.

Latest updates to the BI 655130 Dosing in Palmoplantar Pustulosis Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to include information about a new drug, Spesolimab, for treating Palmoplantar Pustulosis (PPP), while significant details about a previous drug, BI 655130, and its study have been removed.SummaryDifference9%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check36 days agoNo Change Detected
- Check72 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.9%
- Check94 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to BI 655130 Dosing in Palmoplantar Pustulosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BI 655130 Dosing in Palmoplantar Pustulosis Clinical Trial page.